Qiagen has identified Parse Biosciences’ technology as complementary to its sample technology and bioinformatic businesses.
Medtronic reached a critical juncture last month in its quest to build the market for renal denervation, a new device-based ...
CEO Ivan Tornos said multiple factors emerged late in the quarter that caused the shortfall. Zimmer’s shares plunged more ...